Reprint

Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy

Edited by
August 2024
410 pages
  • ISBN978-3-7258-2021-4 (Hardback)
  • ISBN978-3-7258-2022-1 (PDF)

This is a Reprint of the Special Issue Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

This compilation is a reprint of the Special Issue “Therapeutic drug monitoring and pharmacokinetics-based individualization of drug therapy” of the peer-reviewed journal Pharmaceutics (ISSN: 1999-4923). The primary aim of this Special Issue was to provide a platform for presenting the findings of research performed using novel computer software-based approaches for the pharmacokinetic interpretation of the results of therapeutic drug monitoring. The compilation involves nineteen research articles and five review papers published between 2022 and 2024. The areas covered include pharmacotherapy following organ transplant, the treatment of the severely or even critically ill using antiinfectives, precision oncology, mental illness, cystic fibrosis, anticoagulant therapy, the treatment of diabetes, and ophthalmology.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
ganciclovir; lung transplant recipients; cystic fibrosis; therapeutic drug monitoring; covariates; haloperidol; pharmacokinetics; delirium; critical ill; ICU; dapagliflozin; linagliptin; fixed-dose combination products; bioequivalence; busulfan; sulfolane; myelofibrosis; population pharmacokinetics; heart transplantation; acute rejection; therapeutic drug monitoring; tacrolimus; endomyocardial biopsies; therapeutic drug monitoring; pharmacokinetic interactions; heart transplant; precision medicine; clinical practice; gentamicin; population pharmacokinetic modeling; external evaluation; model re-estimation; dosing nomogram; long-acting antiretroviral therapy; cabotegravir; rilpivirine; therapeutic drug monitoring; pharmacokinetics; population pharmacokinetic modeling; pharmacokinetic simulation; TDM; therapeutic drug monitoring; plasma level; PK/PD; dose–effect relationship; cystic fibrosis; LC–MS/MS; CFTR modulators; caftor; ivacaftor; lumacaftor; tezacaftor; elexacaftor; population pharmacokinetic; rivaroxaban; atrial fibrillation; direct oral anticoagulants; Thai patient; cystic fibrosis; therapeutic drug monitoring; tobramycin; pharmacokinetics; model-informed precision dosing; dalbavancin; long-acting; Gram-positive; PK/PD; osteoarticular infections; laparoscopic sleeve gastrectomy; omeprazole; population pharmacokinetic; modeling and simulation; obesity; therapeutic drug monitoring; treatment efficacy; medication adherence; schizophrenia spectrum and other psychotic disorders; bipolar and related disorders; depressive disorder; cefiderocol; pharmacokinetics; PK/PD; antibiotics; drug monitoring; isavuconazole; pediatric; pharmacokinetics; pharmacodynamics; Bayesian; therapeutic drug monitoring; fungal infection; outcomes; oral anticancer drugs; oncology; imatinib; precision pharmacotherapy; therapeutic drug monitoring; cerebrospinal fluid; methotrexate; children; acute lymphoid leukemia; population pharmacokinetics; external validation; non-infectious uveitis (NIU); therapeutic drug monitoring (TDM); pharmacokinetics; pharmacogenetics; biological therapy; limited sampling strategies; population pharmacokinetic modelling; semi-parametric simulation; robustness; therapeutic drug monitoring; area under the curve; AUC; glomerular filtration rate; GFR; tuberculosis; rifampicin; pharmacokinetics; dried blood spots; limited-sampling strategy; pharmacokinetic boosting; pharmacokinetic enhancement; ritonavir; cobicistat; kinase inhibitors; small molecule kinase inhibitors; critical illness; sepsis; kidney injury; biomarkers; pediatric pharmacology; population pharmacokinetics; Bayesian estimation; therapeutic drug monitoring; piperacillin; tazobactam; nonparametric adaptive grid; Bayesian models; pharmacokinetics; model-informed precision dosing; intensive care; n/a